Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with ...

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital. In April, in part 1 of ...

The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...